Ironwood Pharmaceuticals: Pay

Ironwood Pharmaceuticals paid its 3 named executives $4.4M in total in FY2025 (Dec). CEO Thomas McCourt was paid $1.9M of that.

Pay$100 in the stock at the end of FY20 → $32
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Thomas McCourtChief Executive Officer
FY2025 (Dec)Not disclosed
FY2024 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
4 years
Tammi GaskinsSenior Vice President, Chief Commercial Officer
FY2025 (Dec)
FY2024 (Dec)
2 years
Gregory MartiniSenior Vice President, Chief Financial Officer
FY2025 (Dec)
FY2024 (Dec)
2 years

CEO pay against the pay peers

In FY2024 (Dec), the median CEO pay of the 10 peers with pay on file was $10.5M. CEO pay of Ironwood Pharmaceuticals for that year is not on file.

  1. 1Supernus Pharmaceuticals
  2. 2Pacira BioSciences
  3. 3Ultragenyx Pharmaceutical
  4. 4Halozyme Therapeutics
  5. 5INSMED
  6. 6Alkermes plc.
  7. 7Acadia Pharmaceuticals
  8. 8PTC Therapeutics
  9. 9Mirum Pharmaceuticals
  10. 10Travere Therapeutics
  11. 11Ironwood PharmaceuticalsNot disclosed
  12. 12Amicus Therapeutics, Inc.Not disclosed
  13. 13ArdelyxNot disclosed
  14. 14Biocryst PharmaceuticalsNot disclosed
  15. 15Blueprint Medicines CorporationNot disclosed
  16. 16Corcept TherapeuticsNot disclosed
  17. 17Dynavax Technologies CorporationNot disclosed
  18. 18Ligand PharmaceuticalsNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.